Clean version of the pending claims
41-60

41. A pharmaceutical unit dosage form for oral administration, the dosage form comprising a lactose-free core of blended or granulated descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable inert excipients, wherein the core is coated with an inert coating agent.

42. The pharmaceutical unit dosage form of claim 41, wherein the one or more pharmaceutically acceptable inert excipients include one or more wax components.

43. The pharmaceutical unit dosage form of claim 41, wherein the inert coating agent comprises an inert film-forming agent.

44. The pharmaceutical unit dosage form of claim 41, wherein the lactose-free core comprises about 0.1 to 10 mg descarboethoxyloratadine.

45. The pharmaceutical unit dosage form of claim 41, wherein the lactose-free core further comprises an therapeutically effective amount of an analgesic and/or a decongestant.

46. A method of treating histamine-induced disorders, comprising administering to a person in need of such therapy, a pharmaceutical unit dosage form according to claim 41.

47. A method of treating diabetic retinopathy, comprising administering to a person in need of such therapy, a pharmaceutical unit dosage form according to claim 41.

48. A method of treating symptomatic dermographism or dermatitis, comprising administering to a person in need of such therapy, a pharmaceutical unit dosage form according to claim 41.

49. A pharmaceutical unit dosage form for oral administration, the dosage form comprising an anhydrous core of blended or granulated descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable inert excipients, wherein the core is coated with an inert coating agent.

50. The pharmaceutical unit dosage form of claim 49, wherein the lactose-free core comprises about 0.1 to 10 mg descarboethoxyloratadine.

51. The pharmaceutical unit dosage form of claim 49, wherein the lactose-free core further comprises an therapeutically effective amount of an analgesic and/or a decongestant.

52. A method of treating histamine-induced disorders, comprising administering to a person in need of such therapy, a pharmaceutical unit dosage form according to claim 49.

53. A method of treating diabetic retinopathy, comprising administering to a person in need of such therapy, a pharmaceutical unit dosage form according to claim 49.

54. A method of treating symptomatic dermographism or dermatitis, comprising administering to a person in need of such therapy, a pharmaceutical unit dosage form according to claim 49.

55. A pharmaceutical unit dosage form for oral administration, the dosage form comprising a substantially non-hygroscopic core of blended or granulated descarboethoxyloratadine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable inert excipients, wherein the core is coated with an inert coating agent.

56. The pharmaceutical unit dosage form of claim 55, wherein the lactose-free core comprises about 0.1 to 10 mg descarboethoxyloratadine.

57. The pharmaceutical unit dosage form of claim 55, wherein the lactose-free core further comprises an therapeutically effective amount of an analgesic and/or a decongestant.

58. A method of treating histamine-induced disorders, comprising administering to a person in need of such therapy, a pharmaceutical unit dosage form according to claim 55.

59. A method of treating diabetic retinopathy, comprising administering to a person in need of such therapy, a pharmaceutical unit dosage form according to claim 55.

60. A method of treating symptomatic dermographism or dermatitis, comprising administering to a person in need of such therapy, a pharmaceutical unit dosage form according to claim 55.